(Albany, United States) As per DelveInsight’s assessment, globally, the Yellow Fever Pipeline constitutes 10+ key companies continuously working towards developing 10+ Yellow Fever Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Yellow Fever Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Yellow Fever NDA approvals (if any), and product development activities comprising the technology, Yellow Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Yellow Fever Pipeline treatment landscape of the report, click here @ Yellow Fever Pipeline Outlook

 

Key Takeaways from the Yellow Fever Pipeline Report

• DelveInsight’s Yellow Fever Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading companies working in the Yellow Fever Market include BioCryst Pharmaceuticals, Tychan Pte Ltd., CureVac AG, Serum Institute of India Ltd, Sanofi, Emergex Vaccines, Imutex Ltd, and others.
• Promising Yellow Fever Pipeline Therapies in the various stages of development include HydroVax-002 YFV, TY014, GSK 257049, and others.
• On May 2023, Najit Technologies Inc announced a study of phase 1 clinical trials for HydroVax-002 YFV. This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 1 mcg and 5 mcg of HydroVax-002 YFV vaccine given intramuscularly on Day 1 and Day 29 in up to 25 healthy adults healthy adults ≥ 18 and < 50 years of age. The primary objective is to assess the safety, reactogenicity, and tolerability of the HydroVax-002 YFV vaccine administered intramuscularly in a two-dose series on Days 1 and 29 at a dose of 1 mcg or a dose of 5 mcg.
• On May 2023, Sanofi Pasteur, a Sanofi Company announced a study of phase 2 clinical trias for Yellow fever vaccine. Participants will be randomized in a 2:1 ratio to receive a single subcutaneous injection of either the vYF vaccine (380 participants in EU and 80 participants of Chinese origin in Asia) or Stamaril (190 participants in EU and 40 participants of Chinese origin in Asia), on Day 01. 

 

Yellow Fever Overview

Yellow fever is an acute viral haemorrhagic disease transmitted by infected mosquitoes. The yellow fever virus is an arbovirus of the flavivirus genus and is transmitted by mosquitoes, belonging to the Aedes and Haemagogus species.

 

For further information, refer to the detailed Yellow Fever Unmet Needs, click here for Yellow Fever Ongoing Clinical Trial Analysis

 

Yellow Fever Emerging Drugs Profile

 

• Galidesivir: BioCryst Pharmaceuticals

Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika. BioCryst is developing Galidesivir in collaboration with U.S. government agencies and other institutions. Galidesivir is an adenosine nucleoside analog that acts to block viral RNA polymerase. BioCryst Pharmaceuticals completed phase I for Galidesivir.

 

• TY014: Tychan Pte. Ltd.

TY014 is the first monoclonal antibody designed and engineered to treat yellow fever virus infections. TY014 is directed against the envelope (E) protein on the surface of the virus, and prevents viral replication by limiting viral fusion to host cells. Phase 1A of the TY014 study evaluated safety, tolerability and pharmacokinetics of this monoclonal antibody in healthy volunteers.

 

Yellow Fever Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Yellow Fever. The companies which have their Yellow Fever drug candidates in the most advanced stage, i.e. phase I include, BioCryst Pharmaceuticals.

 

Request a sample and discover the recent advances in Yellow Fever Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Yellow Fever Segmentation

 

Yellow Fever Drugs and Companies

• HydroVax-002 YFV: Najit Technologies, Inc.

 

Yellow Fever Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Yellow Fever Therapeutics Market include-

BioCryst Pharmaceuticals, Tychan Pte Ltd., CureVac AG, Serum Institute of India Ltd, Sanofi, Emergex Vaccines, Imutex Ltd, and others.

 

Dive deep into rich insights for drugs for Yellow Fever Pipeline, Click here @ Yellow Fever Unmet Needs and Analyst Views

 

Scope of the Yellow Fever Pipeline Report

• Coverage- Global
• Companies- BioCryst Pharmaceuticals, Tychan Pte Ltd., CureVac AG, Serum Institute of India Ltd, Sanofi, Emergex Vaccines, Imutex Ltd, and others.
• Pipeline Therapies- HydroVax-002 YFV, TY014, GSK 257049, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Yellow Fever Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Yellow Fever: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Yellow Fever – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Yellow Fever Collaboration Deals
9. Mid Stage Products (Phase II)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. Galidesivir: BioCryst Pharmaceuticals
14. Preclinical Products
15. EMX-001: Emergex Vaccines
16. Drug profiles in the detailed report…..
17. Inactive Products
18. Yellow Fever Key Companies
19. Yellow Fever Key Products
20. Yellow Fever- Unmet Needs
21. Yellow Fever- Market Drivers and Barriers
22. Yellow Fever- Future Perspectives and Conclusion
23. Yellow Fever Analyst Views
24. Yellow Fever Key Companies
25. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services